Showing results (81-90 of 287) with videos related to
Sort By:
Pageof 29
Psychopharmacologia|October 14, 1975
The effect of lithium treatment on manic symptoms and levels of monoamine metabolites in cerebrospinal fluid of manic depressive patientsB Fyrö, U Petterson, G SedvallScandinavian Journal of Gastroenterology|January 1, 1982
Psychic disturbances in adult coeliac disease. III. Reduced central monoamine metabolism and signs of depressionC Hallert, J Aström, G SedvallJournal of Chromatography|October 11, 1979
Quantitative analysis of sulpiride in body fluids by high-performance liquid chromatography with fluorescence detectionG Alfredsson, G Sedvall, F A WieselNeuroscience|January 1, 1989
Dopamine-regulated phosphorylation of synaptic vesicle-associated proteins in rat neostriatum and substantia nigraS I Walaas, G Sedvall, P GreengardPsychiatry Research|October 7, 1996
Test-retest reliability of central [11C]raclopride binding at high D2 receptor occupancy. A PET study in haloperidol-treated patientsS Nyberg, L Farde, C HalldinJournal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|February 6, 1999
Localization of 5-HT1A receptors in the living human brain using [carbonyl-11C]WAY-100635: PET with anatomic standardization techniqueH Ito, C Halldin, L FardeNeuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology|January 1, 1997
A PET study of 5-HT2 and D2 dopamine receptor occupancy induced by olanzapine in healthy subjectsS Nyberg, L Farde, C HalldinArchives of General Psychiatry|October 24, 1997
Delayed normalization of central D2 dopamine receptor availability after discontinuation of haloperidol decanoate. Preliminary findingsS Nyberg, L Farde, C HalldinNuclear Medicine and Biology|May 1, 1994
Fluorine-18-labelled NCQ 115, a selective dopamine D-2 receptor ligand. Preparation and positron emission tomographyC Halldin, T Högberg, L FardeCurrent Pharmaceutical Design|January 5, 2002
PET studies with carbon-11 radioligands in neuropsychopharmacological drug developmentC Halldin, B Gulyás, L FardePageof 29